VAXSYNA, INC.

FRANKLIN, NH · Founded 2021 · CIK 0001947994 · Biotech · Private

modifiable vaccine platform for infectious disease development

vaxsyna.com →
Grants
$437K
2 awards
Sector median: 1
Raised
—
1 Form D · Sep 2022
49 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Low cost, Broad Spectrum Cancer Vaccine Targeting Human Papillomavirus$315,874
Federal grantDepartment of Health and Human Services · Phase I · Low cost, Broad Spectrum Cancer Vaccine Targeting Human Papillomavirus$121,329
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2726DOTQUANT LLC——
2727Metaphore Biotechnologies——
2728Cellarity——
2729VAXSYNA, INC.——
2730IMMUNOGENIK, INC.——
2731EPIGENTER, LLC——
2732OMETA LABS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Joseph HunterExecutive Officer
  • Kaitlyn MorseExecutive Officer
  • Mary PardheExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.